Renal cell carcinoma survival risk biomarker group, diagnostic product and application

A technology of biomarkers and products, applied in the field of disease diagnosis, can solve problems such as non-response to treatment and occurrence of drug resistance

Pending Publication Date: 2021-09-28
BEIJING MEDINTELL BIOMED CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although immunotherapy has made great progress in the treatment of kidney cancer, not all patients can benefit from it. Some patients do not respond to immune checkpoint inhibitor treatment, and a small number of patients develop resistance shortly after drug application. Drugs, and the existence of immune-related toxicity and other issues (Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade[J]. Cancer J, 2018,24(1):47-53. )

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Renal cell carcinoma survival risk biomarker group, diagnostic product and application
  • Renal cell carcinoma survival risk biomarker group, diagnostic product and application
  • Renal cell carcinoma survival risk biomarker group, diagnostic product and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0051] The present invention provides, in part, kits, genetic signatures and methods of detecting such genetic signatures / biomarkers to perform analysis of renal cancer tissue samples, in one aspect, the present invention provides a genetic signature associated with renal cancer survival, This genetic signature can classify an individual's risk of poor prognosis and help guide physicians in choosing treatment strategies.

[0052] The use of "and / or" herein should be considered as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" would be considered a specific disclosure of each of (i) A, (ii) B, and (iii) A and B, as if each were individually listed herein Same.

[0053] As used herein, the terms "biomarker", "marker" and "genetic signature" are interchangeable and refer to a biomarker obtained from a control subject, such as a subject with kidney cancer with a poor prognosis. Molecules that are dif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a renal cell carcinoma survival risk biomarker group, a diagnostic product and application, and particularly relates to biomarkers SLC11A1, TEK and THRB. Single factor Cox analysis finds that immune related genes SLC11A1, TEK and THRB are related to survival of renal cell carcinoma, a prediction model is constructed though LASSO Cox analysis, and it is found that the prediction model constructed by the above genes can independently predict prognosis of renal cell carcinoma.

Description

technical field [0001] The present invention relates to the field of disease diagnosis, more specifically, the present invention relates to a biomarker group of survival risk of renal cancer, diagnostic products and applications. Background technique [0002] Renal Cell Carcinoma (RCC) is one of the most common malignant tumors of the urinary system. According to histological classification, RCC is divided into various subtypes, among which clear cell renal cell carcinoma (ccRCC) is the The main subtype of renal cell carcinoma, accounting for about 75-80% of renal cell carcinoma (Pavlovich CP, Schmidt LS, PhillipsJL. The genetic basis of renal cell carcinoma[J]. Urol Clin North Am, 2003,30(3):437-54 , vii.), other types include papillary carcinoma, chromophobe cell carcinoma, Bellini duct (collecting duct) carcinoma, etc. Patients with clear cell renal cell carcinoma have the highest mortality and metastasis rates, with approximately 400,000 new cases and 175,000 deaths wor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574G01N33/68G01N33/573G16B25/10G16B30/00G16B40/00
CPCC12Q1/6886G01N33/57438G01N33/57484G01N33/57488G01N33/68G01N33/573G01N33/74G16B25/10G16B30/00G16B40/00C12Q2600/118C12Q2600/158G01N2333/47G01N2333/912G01N2333/72
Inventor 杨承刚王丹刘乐凯
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap